Completed PHASE3 INTERVENTIONAL 2-arm NCT00309569

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

A Randomized Phase III Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment Hormone Receptor-negative Breast Cancer Patients

Sponsor: Austrian Breast & Colorectal Cancer Study Group

Conditions Early Stage Breast Cancer

Interventions Cyclophosphamide Epirubicin Fluorouracil Methotrexate Surgery

Updated 5 times since 2017 Last updated: Oct 13, 2020 Started: Oct 31, 1991 Primary completion: Sep 30, 2000 Completion: Sep 30, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00309569, this PHASE3 trial focuses on Early Stage Breast Cancer and remains completed. Sponsored by Austrian Breast & Colorectal Cancer Study Group, it has been updated 5 times since 1991, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2020 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Nov 2020 [monthly]

Completed PHASE3

First recorded

Oct 1991

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Austrian Breast & Colorectal Cancer Study Group

Data source: Austrian Breast & Colorectal Cancer Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.